Although there is insufficient evidence directly linking ADGRF5 to human pulmonary fibrosis, its roles in airway inflammation, fibrosis-related gene expression, and immune regulation suggest that ADGRF5 may serve as a potential therapeutic target or biomarker for fibrotic lung diseases [47]. This evidence concerns the gene ADGRF5 and pulmonary fibrosis.